DPMAS is Dual Plasma Molecular Adsorption System, which is a combined artificial liver treatment mode. It adopts the combined application of two resin adsorption columns, the new bilirubin adsorption column and the hemoperfusion device. The bilirubin adsorption column is a specific adsorption column for bilirubin, which specifically adsorbs ferrous erythrocyanin and bile acids; and the hemoperfusion device adsorbs medium and large molecule toxins, cytokines, inflammatory mediators and bilirubin. The combined application of the two increases the clearance capacity of bilirubin and enhances the clearance of toxins, inflammatory mediators and other harmful substances while improving the symptoms of jaundice, which plays the role of both symptomatic and symptomatic treatment, improves the success rate of clinical treatment, and markedly improves the prognosis of patients. Plasma adsorption is the first to enter the plasma separator to separate the formed components of blood (blood cells, platelets) and plasma after blood is drawn out, and the formed components are infused back into the patient’s body, and the plasma then enters the adsorber to adsorb and remove some specific substances therein, and the plasma is infused back into the patient’s body after adsorption. Plasma adsorption is mainly divided into molecular sieve adsorption and immune adsorption according to the characteristics of the adsorbent. 1, molecular sieve adsorption: i.e., the use of the molecular sieve principle through the adsorbent carries the charge and pores, non-specific adsorption of charge and the molecular size of the substance corresponding to it; 2, immune adsorption: i.e., the use of highly specific antigen-antibody reaction or a specific physicochemical affinity of the substances (ligands) combined in the adsorbent material (carrier), used for the adsorption of some specific substances. carrier) for the removal of specific substances (ligands) from plasma or whole blood.